CNBX Pharmaceuticals Inc (CNBX)
CNBX Pharmaceuticals Inc. is a clinical-stage common stock issuer listed on OTC Markets in the healthcare sector. The company focuses on discovering, developing, and commercializing cannabinoid-based products and technologies for cancer-related indications. Its lead candidate, Cannabics SR, is an oral capsule being developed for patients with advanced cancer and cancer anorexia cachexia syndrome. CNBX is also advancing a pipeline that includes PLP-33 for local treatment of sessile colorectal polyps during colonoscopy, BRST-33 for breast cancer, MLN-33 for melanoma, PRST-33 for prostate cancer, and RCC-33, an oral cannabinoid formulation being developed for colorectal cancer. Formerly known as Cannabics Pharmaceuticals Inc., the company adopted its current name in March 2022 and was incorporated in 2004. It is based in Bethesda, Maryland.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-CNBX
|
—
|
—
|
Fair
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
November 30, 2026
|
-0.3x
|
-0.1x
|
—
|
160.576 K
|
1.318 M
|
87.9%
|
100.0%
|
-3,159.1
|
—
|
33.4%
|
